Trial Outcomes & Findings for Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat Non-Hodgkin's Lymphoma (NHL) (NCT NCT01685008)

Results Overview

Proportion of patients with Complete Remission (CR; disappearance of all evidence of disease) or Partial Remission (PR; regression of measurable disease and no new sites), assessed as per the 2007 International Working Group (IWG) response criteria by radiographic evaluations (CT, PET, MRI, or other).

Recruitment status

COMPLETED

Study phase

PHASE2

Target enrollment

92 participants

Primary outcome timeframe

From first dose until Follow-up Visit 12, up to 4.5 years

Results posted on

2023-11-07

Participant Flow

All patients who fulfilled all the inclusion criteria and none of the exclusion criteria were enrolled and received MOR00208 infusion. Per planned analyses, patient disposition and treatment discontinuation is summarized by NHL subtype.

Participant milestones

Participant milestones
Measure	FL Subtype Patients with follicular lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	DLBCL Subtype Patients with diffuse large B-cell lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	MCL Subtype Patients with mantle cell lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	Other iNHL Patients with other indolent non-Hodgkin's lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.
Main Study Treatment (Cycles 1 - 2) STARTED	34	35	12	11
Main Study Treatment (Cycles 1 - 2) COMPLETED	30	25	10	10
Main Study Treatment (Cycles 1 - 2) NOT COMPLETED	4	10	2	1
Cycle 3 and Maintenance Treatment STARTED	30	25	10	10
Cycle 3 and Maintenance Treatment Began Cycle 3 Treatment	25	13	5	7
Cycle 3 and Maintenance Treatment Entered Maintenance Phase Treatment	8	6	0	2
Cycle 3 and Maintenance Treatment COMPLETED	0	1	0	0
Cycle 3 and Maintenance Treatment NOT COMPLETED	30	24	10	10

Reasons for withdrawal

Reasons for withdrawal
Measure	FL Subtype Patients with follicular lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	DLBCL Subtype Patients with diffuse large B-cell lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	MCL Subtype Patients with mantle cell lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	Other iNHL Patients with other indolent non-Hodgkin's lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.
Main Study Treatment (Cycles 1 - 2) Adverse Event	2	0	0	1
Main Study Treatment (Cycles 1 - 2) Physician Decision	0	2	0	0
Main Study Treatment (Cycles 1 - 2) Protocol Violation	0	1	0	0
Main Study Treatment (Cycles 1 - 2) Progressive Disease	2	4	1	0
Main Study Treatment (Cycles 1 - 2) Death	0	3	1	0

Baseline Characteristics

Height was not collected at Screening for 2 patients (minor protocol noncompliance)

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	FL Subtype n=34 Participants Patients with follicular lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	DLBCL Subtype n=35 Participants Patients with diffuse large B-cell lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	MCL Subtype n=12 Participants Patients with mantle cell lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	Other iNHL n=11 Participants Patients with other indolent non-Hodgkin's lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	Total n=92 Participants Total of all reporting groups
Age, Categorical <=18 years	0 Participants n=34 Participants	0 Participants n=35 Participants	0 Participants n=12 Participants	0 Participants n=11 Participants	0 Participants n=92 Participants
Age, Categorical Between 18 and 65 years	19 Participants n=34 Participants	16 Participants n=35 Participants	6 Participants n=12 Participants	2 Participants n=11 Participants	43 Participants n=92 Participants
Age, Categorical >=65 years	15 Participants n=34 Participants	19 Participants n=35 Participants	6 Participants n=12 Participants	9 Participants n=11 Participants	49 Participants n=92 Participants
Age, Continuous	62.88 years n=34 Participants	66.71 years n=35 Participants	64.92 years n=12 Participants	70.91 years n=11 Participants	65.57 years n=92 Participants
Sex: Female, Male Female	18 Participants n=34 Participants	11 Participants n=35 Participants	1 Participants n=12 Participants	6 Participants n=11 Participants	36 Participants n=92 Participants
Sex: Female, Male Male	16 Participants n=34 Participants	24 Participants n=35 Participants	11 Participants n=12 Participants	5 Participants n=11 Participants	56 Participants n=92 Participants
Race/Ethnicity, Customized Asian	0 Participants n=34 Participants	1 Participants n=35 Participants	0 Participants n=12 Participants	0 Participants n=11 Participants	1 Participants n=92 Participants
Race/Ethnicity, Customized Black or African American	0 Participants n=34 Participants	0 Participants n=35 Participants	1 Participants n=12 Participants	0 Participants n=11 Participants	1 Participants n=92 Participants
Race/Ethnicity, Customized White	32 Participants n=34 Participants	33 Participants n=35 Participants	11 Participants n=12 Participants	11 Participants n=11 Participants	87 Participants n=92 Participants
Race/Ethnicity, Customized Other	2 Participants n=34 Participants	1 Participants n=35 Participants	0 Participants n=12 Participants	0 Participants n=11 Participants	3 Participants n=92 Participants
Height	170.26 cm n=34 Participants • Height was not collected at Screening for 2 patients (minor protocol noncompliance)	168.24 cm n=33 Participants • Height was not collected at Screening for 2 patients (minor protocol noncompliance)	171.00 cm n=12 Participants • Height was not collected at Screening for 2 patients (minor protocol noncompliance)	167.64 cm n=11 Participants • Height was not collected at Screening for 2 patients (minor protocol noncompliance)	169.30 cm n=90 Participants • Height was not collected at Screening for 2 patients (minor protocol noncompliance)
Weight	78.62 kg n=34 Participants	75.52 kg n=35 Participants	82.52 kg n=12 Participants	71.53 kg n=11 Participants	77.10 kg n=92 Participants
BMI	27.26 kg/m^2 n=34 Participants • Height was not collected at Screening for 2 patients (minor protocol noncompliance)	26.52 kg/m^2 n=33 Participants • Height was not collected at Screening for 2 patients (minor protocol noncompliance)	28.03 kg/m^2 n=12 Participants • Height was not collected at Screening for 2 patients (minor protocol noncompliance)	25.36 kg/m^2 n=11 Participants • Height was not collected at Screening for 2 patients (minor protocol noncompliance)	26.86 kg/m^2 n=90 Participants • Height was not collected at Screening for 2 patients (minor protocol noncompliance)
NHL Subtype Follicular lymphoma	34 Participants n=34 Participants	0 Participants n=35 Participants	0 Participants n=12 Participants	0 Participants n=11 Participants	34 Participants n=92 Participants
NHL Subtype Diffuse large B-cell lymphoma	0 Participants n=34 Participants	35 Participants n=35 Participants	0 Participants n=12 Participants	0 Participants n=11 Participants	35 Participants n=92 Participants
NHL Subtype Mantle cell lymphoma	0 Participants n=34 Participants	0 Participants n=35 Participants	12 Participants n=12 Participants	0 Participants n=11 Participants	12 Participants n=92 Participants
NHL Subtype Other indolent NHL	0 Participants n=34 Participants	0 Participants n=35 Participants	0 Participants n=12 Participants	11 Participants n=11 Participants	11 Participants n=92 Participants

PRIMARY outcome

Timeframe: From first dose until Follow-up Visit 12, up to 4.5 years

Population: The Intent-to-treat (ITT) Population consisted of all patients who received at least one dose of study drug. Patients without any post-Baseline assessment of NHL response were included as non-responders. Per pre-specified analysis plan, efficacy analyses are summarized overall, by NHL subtype, and for the combined group comprising FL patients + other iNHL patients.

Proportion of patients with Complete Remission (CR; disappearance of all evidence of disease) or Partial Remission (PR; regression of measurable disease and no new sites), assessed as per the 2007 International Working Group (IWG) response criteria by radiographic evaluations (CT, PET, MRI, or other).

Outcome measures

Outcome measures
Measure	Total n=92 Participants All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	FL Subtype n=34 Participants Patients with follicular lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	DLBCL Subtype n=35 Participants Patients with diffuse large B-cell lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	MCL Subtype n=12 Participants Patients with mantle cell lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	Other iNHL n=11 Participants Patients with other indolent non-Hodgkin's lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	FL + Other iNHL n=45 Participants Combined group of patients with follicular lymphoma and patients with other indolent non-Hodgkin's lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.
Overall Response Rate (ORR) Complete remission	6 Participants	2 Participants	2 Participants	0 Participants	2 Participants	4 Participants
Overall Response Rate (ORR) Partial remission	16 Participants	8 Participants	7 Participants	0 Participants	1 Participants	9 Participants

SECONDARY outcome

Timeframe: From first dose until Follow-up Visit 12, up to 4.5 years

Population: The ITT Population consisted of all patients who received at least one dose of study drug. Patients without any post-Baseline assessment of NHL response were included as non-responders. Per pre-specified analysis plan, efficacy analyses are summarized overall, by NHL subtype, and for the combined group comprising FL patients + other iNHL patients.

Proportion of patients with Stable Disease (failure to attain CR/PR with no progressive disease)

Outcome measures

Outcome measures
Measure	Total n=92 Participants All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	FL Subtype n=34 Participants Patients with follicular lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	DLBCL Subtype n=35 Participants Patients with diffuse large B-cell lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	MCL Subtype n=12 Participants Patients with mantle cell lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	Other iNHL n=11 Participants Patients with other indolent non-Hodgkin's lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	FL + Other iNHL n=45 Participants Combined group of patients with follicular lymphoma and patients with other indolent non-Hodgkin's lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.
Stable Disease (SD) Rate	31 Participants	16 Participants	5 Participants	6 Participants	4 Participants	20 Participants

SECONDARY outcome

Timeframe: From first dose until Follow-up Visit 12, up to 4.5 years

Population: Patients in the ITT Population who had any response (CR or PR) during the study. Per pre-specified analysis plan, efficacy analyses are summarized overall, by NHL subtype, and for the combined group comprising FL patients + other iNHL patients.

Time from first CR or PR to first documentation of relapse/progression (any new lesion or increase by ≥ 50% of previously identified site)

Outcome measures

Outcome measures
Measure	Total n=22 Participants All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	FL Subtype n=10 Participants Patients with follicular lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	DLBCL Subtype n=9 Participants Patients with diffuse large B-cell lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	MCL Subtype Patients with mantle cell lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	Other iNHL n=3 Participants Patients with other indolent non-Hodgkin's lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	FL + Other iNHL n=13 Participants Combined group of patients with follicular lymphoma and patients with other indolent non-Hodgkin's lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.
Duration of Response (DoR)	24.0 months Interval 11.1 to Patients who showed a response during the study but did not have documented progression (as described in the pre-specified analysis plan) were considered censored. Due to this statistical data censoring, there was an insufficient number of patients with events in the analysis population to compute median and/or confidence interval(s).	24.0 months Interval 2.6 to Patients who showed a response during the study but did not have documented progression (as described in the pre-specified analysis plan) were considered censored. Due to this statistical data censoring, there was an insufficient number of patients with events in the analysis population to compute median and/or confidence interval(s).	20.1 months Interval 1.1 to Patients who showed a response during the study but did not have documented progression (as described in the pre-specified analysis plan) were considered censored. Due to this statistical data censoring, there was an insufficient number of patients with events in the analysis population to compute median and/or confidence interval(s).	—	NA months No responders had documented progression, therefore all patients in this population were censored and no median or confidence intervals were applicable.	NA months Interval 3.6 to Patients who showed a response during the study but did not have documented progression (as described in the pre-specified analysis plan) were considered censored. Due to this statistical data censoring, there was an insufficient number of patients with events in the analysis population to compute median and/or confidence interval(s).

SECONDARY outcome

Timeframe: From first dose until Follow-up Visit 12, up to 4.5 years

Population: Patients in the ITT Population with documented progression of disease. Per pre-specified analysis plan, efficacy analyses are summarized overall, by NHL subtype, and for the combined group comprising FL patients + other iNHL patients.

Time from first dosing until documentation of progression or death due to lymphoma

Outcome measures

Outcome measures
Measure	Total n=76 Participants All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	FL Subtype n=31 Participants Patients with follicular lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	DLBCL Subtype n=25 Participants Patients with diffuse large B-cell lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	MCL Subtype n=11 Participants Patients with mantle cell lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	Other iNHL n=9 Participants Patients with other indolent non-Hodgkin's lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	FL + Other iNHL n=40 Participants Combined group of patients with follicular lymphoma and patients with other indolent non-Hodgkin's lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.
Time to Progression (TTP)	5.4 months Interval 3.4 to 12.0	8.8 months Interval 5.4 to 20.5	3.1 months Interval 2.1 to 15.4	3.0 months Interval 1.8 to Patients who did not have documented radiological progression (as described in the pre-specified analysis plan) were considered censored. Due to this statistical data censoring, there was an insufficient number of patients with events in the analysis population to compute median and/or confidence interval(s).	NA months Interval 2.0 to Patients who did not have documented radiological progression (as described in the pre-specified analysis plan) were considered censored. Due to this statistical data censoring, there was an insufficient number of patients with events in the analysis population to compute median and/or confidence interval(s).	6.6 months Interval 5.3 to 20.5

SECONDARY outcome

Timeframe: From first dose until Follow-up Visit 12, up to 4.5 years

Population: Patients in the ITT Population with documented progression of disease or death from any cause. Per pre-specified analysis plan, efficacy analyses are summarized overall, by NHL subtype, and for the combined group comprising FL patients + other iNHL patients.

Time from first dosing until progression or death due to any case

Outcome measures

Outcome measures
Measure	Total n=80 Participants All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	FL Subtype n=31 Participants Patients with follicular lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	DLBCL Subtype n=28 Participants Patients with diffuse large B-cell lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	MCL Subtype n=12 Participants Patients with mantle cell lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	Other iNHL n=9 Participants Patients with other indolent non-Hodgkin's lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	FL + Other iNHL n=40 Participants Combined group of patients with follicular lymphoma and patients with other indolent non-Hodgkin's lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.
Progression-free Survival (PFS)	5.4 months Interval 3.2 to 9.9	8.8 months Interval 5.4 to 20.5	2.7 months Interval 2.1 to 13.2	2.1 months Interval 1.7 to Patients who did not have documented radiological progression, or death occurred beyond a pre-specified time frame (as described in the pre-specified analysis plan) were considered censored. Due to this statistical data censoring, there was an insufficient number of patients with events in the analysis population to compute median and/or confidence interval(s).	NA months Interval 2.0 to Patients who did not have documented radiological progression, or death occurred beyond a pre-specified time frame (as described in the pre-specified analysis plan) were considered censored. Due to this statistical data censoring, there was an insufficient number of patients with events in the analysis population to compute median and/or confidence interval(s).	6.6 months Interval 5.3 to 20.5

SECONDARY outcome

Timeframe: From first dose until 30 days after last dose of MOR00208, up to 8.5 years

Population: The Safety Population consisted of all patients who received at least one dose of study drug. Per pre-specified analysis plan, adverse event analyses are summarized overall, by NHL subtype, and for the combined group comprising FL patients + other iNHL patients.

Number of patients with treatment-emergent AEs rated Mild, Moderate, and Severe

Outcome measures

Outcome measures
Measure	Total n=92 Participants All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	FL Subtype n=34 Participants Patients with follicular lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	DLBCL Subtype n=35 Participants Patients with diffuse large B-cell lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	MCL Subtype n=12 Participants Patients with mantle cell lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	Other iNHL n=11 Participants Patients with other indolent non-Hodgkin's lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	FL + Other iNHL n=45 Participants Combined group of patients with follicular lymphoma and patients with other indolent non-Hodgkin's lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.
Incidence and Severity of Adverse Events (AEs) Mild	29 Participants	10 Participants	12 Participants	1 Participants	6 Participants	16 Participants
Incidence and Severity of Adverse Events (AEs) Moderate	20 Participants	8 Participants	8 Participants	2 Participants	2 Participants	10 Participants
Incidence and Severity of Adverse Events (AEs) Severe	6 Participants	2 Participants	4 Participants	0 Participants	0 Participants	2 Participants

SECONDARY outcome

Timeframe: From first dose until Follow-up Visit 3, up to 7 months

Population: The Safety Population (all patients who received at least one dose of study drug). Per pre-specified analysis plan, statistical summaries are provided overall, by NHL subtype, and for the combined group comprising FL patients + other iNHL patients.

Number of patients with at least one positive (+ve) post-Baseline sample containing positive anti-MOR00208 antibodies; Baseline (pre-dose) sample has to be tested negative (-ve)

Outcome measures

Outcome measures
Measure	Total n=92 Participants All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	FL Subtype n=34 Participants Patients with follicular lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	DLBCL Subtype n=35 Participants Patients with diffuse large B-cell lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	MCL Subtype n=12 Participants Patients with mantle cell lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	Other iNHL n=11 Participants Patients with other indolent non-Hodgkin's lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	FL + Other iNHL n=45 Participants Combined group of patients with follicular lymphoma and patients with other indolent non-Hodgkin's lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.
Number and Proportion of Patients Who Potentially Developed Anti-MOR00208 Antibodies and Semiquantitative Anti-MOR00208 Antibody Assessments Yes (at least 1 +ve post-Baseline sample, including +ve last sample; Baseline must be -ve)	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number and Proportion of Patients Who Potentially Developed Anti-MOR00208 Antibodies and Semiquantitative Anti-MOR00208 Antibody Assessments No (Baseline and all post-Baseline samples are -ve)	82 Participants	31 Participants	31 Participants	10 Participants	10 Participants	41 Participants
Number and Proportion of Patients Who Potentially Developed Anti-MOR00208 Antibodies and Semiquantitative Anti-MOR00208 Antibody Assessments Transient (at least 1 +ve post-Baseline sample but -ve last sample; Baseline must be -ve)	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Number and Proportion of Patients Who Potentially Developed Anti-MOR00208 Antibodies and Semiquantitative Anti-MOR00208 Antibody Assessments Not evaluable (pre-dose Baseline sample tested +ve)	5 Participants	3 Participants	1 Participants	1 Participants	0 Participants	3 Participants
Number and Proportion of Patients Who Potentially Developed Anti-MOR00208 Antibodies and Semiquantitative Anti-MOR00208 Antibody Assessments Missing (no post-Baseline measurement available)	5 Participants	0 Participants	3 Participants	1 Participants	1 Participants	1 Participants

SECONDARY outcome

Timeframe: Estimated from first dose (samples taken on first day of dosing at pre-dose, end of infusion, after 1 hour, 4 hours, 24 hours, and pre-dose on Day 8)

Population: The PK Population included all patients who had at least one quantifiable serum MOR00208 concentration. PK parameters were calculated as data permitted. Per pre-specified analysis plan, statistical summaries are provided overall, by NHL subtype, and for the combined group comprising FL patients + other iNHL patients.

The highest concentration of MOR00208 measured in serum

Outcome measures

Outcome measures
Measure	Total n=85 Participants All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	FL Subtype n=33 Participants Patients with follicular lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	DLBCL Subtype n=32 Participants Patients with diffuse large B-cell lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	MCL Subtype n=11 Participants Patients with mantle cell lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	Other iNHL n=9 Participants Patients with other indolent non-Hodgkin's lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	FL + Other iNHL n=42 Participants Combined group of patients with follicular lymphoma and patients with other indolent non-Hodgkin's lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.
Pharmacokinetic (PK) Parameter: Maximum Serum Concentration Observed (Cmax) of MOR00208	263.1 μg/mL Standard Deviation 111.35	276.6 μg/mL Standard Deviation 73.10	253.4 μg/mL Standard Deviation 157.79	260.0 μg/mL Standard Deviation 69.85	251.5 μg/mL Standard Deviation 70.31	271.2 μg/mL Standard Deviation 72.42

SECONDARY outcome

Timeframe: Estimated from first dose (samples taken on first day of dosing at pre-dose, end of infusion, after 1 hour, 4 hours, 24 hours, and pre-dose on Day 8)

Population: The PK Population included all patients who had at least one quantifiable serum MOR00208 concentration. PK parameters were calculated as data permitted. Per pre-specified analysis plan, statistical summaries are provided overall, by NHL subtype, and for the combined group comprising FL patients + other iNHL patients.

The time to highest concentration of MOR00208 measured in serum

Outcome measures

Outcome measures
Measure	Total n=85 Participants All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	FL Subtype n=33 Participants Patients with follicular lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	DLBCL Subtype n=32 Participants Patients with diffuse large B-cell lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	MCL Subtype n=11 Participants Patients with mantle cell lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	Other iNHL n=9 Participants Patients with other indolent non-Hodgkin's lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	FL + Other iNHL n=42 Participants Combined group of patients with follicular lymphoma and patients with other indolent non-Hodgkin's lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.
PK Parameter: Time to Maximum Serum Concentration Observed (Tmax) of MOR00208	5.8 hours Standard Deviation 17.46	4.7 hours Standard Deviation 5.27	8.5 hours Standard Deviation 27.99	3.0 hours Standard Deviation 1.03	3.4 hours Standard Deviation 1.38	4.4 hours Standard Deviation 4.72

SECONDARY outcome

Timeframe: Estimated from first dose (samples taken on first day of dosing at pre-dose, end of infusion, after 1 hour, 4 hours, 24 hours, and pre-dose on Day 8)

Population: The PK Population included all patients who had at least one quantifiable serum MOR00208 concentration. PK parameters were calculated as data permitted. Per pre-specified analysis plan, statistical summaries are provided overall, by NHL subtype, and for the combined group comprising FL patients + other iNHL patients.

The last quantifiable concentration from the first dose of MOR00208

Outcome measures

Outcome measures
Measure	Total n=85 Participants All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	FL Subtype n=33 Participants Patients with follicular lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	DLBCL Subtype n=32 Participants Patients with diffuse large B-cell lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	MCL Subtype n=11 Participants Patients with mantle cell lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	Other iNHL n=9 Participants Patients with other indolent non-Hodgkin's lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	FL + Other iNHL n=42 Participants Combined group of patients with follicular lymphoma and patients with other indolent non-Hodgkin's lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.
PK Parameter: Apparent Trough Serum Concentration Before Dosing (Clast) of MOR00208	81.0 μg/mL Standard Deviation 36.66	88.6 μg/mL Standard Deviation 39.50	69.6 μg/mL Standard Deviation 28.96	82.4 μg/mL Standard Deviation 34.54	92.2 μg/mL Standard Deviation 47.23	89.3 μg/mL Standard Deviation 40.69

SECONDARY outcome

Timeframe: Estimated from first dose (samples taken on first day of dosing at pre-dose, end of infusion, after 1 hour, 4 hours, 24 hours, and pre-dose on Day 8)

Population: The PK Population included all patients who had at least one quantifiable serum MOR00208 concentration. PK parameters were calculated as data permitted. Per pre-specified analysis plan, statistical summaries are provided overall, by NHL subtype, and for the combined group comprising FL patients + other iNHL patients.

Area under the concentration curve. The time curve from time zero (0) to the time that the last concentration above the lower limit of quantification (LLQ) is observed.

Outcome measures

Outcome measures
Measure	Total n=85 Participants All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	FL Subtype n=33 Participants Patients with follicular lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	DLBCL Subtype n=32 Participants Patients with diffuse large B-cell lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	MCL Subtype n=11 Participants Patients with mantle cell lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	Other iNHL n=9 Participants Patients with other indolent non-Hodgkin's lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	FL + Other iNHL n=42 Participants Combined group of patients with follicular lymphoma and patients with other indolent non-Hodgkin's lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.
PK Parameter: Area Under the Concentration Curve From Dose Time Zero to the Time the Last Quantifiable Concentration is Observed (AUC[0-t]) of MOR00208	21942.5 h*μg/mL Standard Deviation 11847.35	25088.6 h*μg/mL Standard Deviation 16245.82	19106.3 h*μg/mL Standard Deviation 8170.03	21617.1 h*μg/mL Standard Deviation 4577.21	20888.5 h*μg/mL Standard Deviation 7669.67	24188.6 h*μg/mL Standard Deviation 14849.65

SECONDARY outcome

Timeframe: Estimated from final dose (samples collected on the last day of Cycle 3 [C3D28; each cycle is 28 days long], and Follow-up Visits 1 [C3D28 + 4 weeks], 2 [C3D28 + 10 weeks], and 3 [C3D28 + 16 weeks])

Population: The PK Population included all patients who had at least one quantifiable serum MOR00208 concentration. PK parameters were calculated as data permitted. Per pre-specified analysis plan, statistical summaries are provided overall, by NHL subtype, and for the combined group comprising FL patients + other iNHL patients.

Area under the concentration curve. The time curve from time zero (0) to infinity (inf), where infinity is computed from AUC0-t + \[Ct/λZ)\]. Ct is calculated from the concentration at the last sampling time at which the sample is above LLQ.

Outcome measures

Outcome measures
Measure	Total n=91 Participants All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	FL Subtype n=33 Participants Patients with follicular lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	DLBCL Subtype n=35 Participants Patients with diffuse large B-cell lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	MCL Subtype n=12 Participants Patients with mantle cell lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	Other iNHL n=11 Participants Patients with other indolent non-Hodgkin's lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	FL + Other iNHL n=44 Participants Combined group of patients with follicular lymphoma and patients with other indolent non-Hodgkin's lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.
PK Parameter: Area Under the Concentration Curve From Dose Time Zero to Infinity (AUC[0-inf]) of MOR00208	NA h*μg/mL Standard Deviation NA There were not sufficient data available to allow parameter estimation.	NA h*μg/mL Standard Deviation NA There were not sufficient data available to allow parameter estimation.	NA h*μg/mL Standard Deviation NA There were not sufficient data available to allow parameter estimation.	NA h*μg/mL Standard Deviation NA There were not sufficient data available to allow parameter estimation.	NA h*μg/mL Standard Deviation NA There were not sufficient data available to allow parameter estimation.	NA h*μg/mL Standard Deviation NA There were not sufficient data available to allow parameter estimation.

SECONDARY outcome

Timeframe: Estimated from final dose (samples collected on the last day of Cycle 3 [C3D28; each cycle is 28 days long], and Follow-up Visits 1 [C3D28 + 4 weeks], 2 [C3D28 + 10 weeks], and 3 [C3D28 + 16 weeks])

Population: The PK Population included all patients who had at least one quantifiable serum MOR00208 concentration. PK parameters were calculated as data permitted. Per pre-specified analysis plan, statistical summaries are provided overall, by NHL subtype, and for the combined group comprising FL patients + other iNHL patients.

Apparent terminal rate constant calculated from the regression analysis (slope) from the log-transformed measured concentrations on the terminal phase of the time-point concentration curve

Outcome measures

Outcome measures
Measure	Total n=12 Participants All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	FL Subtype n=9 Participants Patients with follicular lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	DLBCL Subtype Patients with diffuse large B-cell lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	MCL Subtype n=2 Participants Patients with mantle cell lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	Other iNHL n=1 Participants Patients with other indolent non-Hodgkin's lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	FL + Other iNHL n=10 Participants Combined group of patients with follicular lymphoma and patients with other indolent non-Hodgkin's lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.
PK Parameter: Apparent Terminal Rate Constant (λz) of MOR00208	0.00214 1/h Standard Deviation 0.000665	0.00214 1/h Standard Deviation 0.000707	—	0.00207 1/h Standard Deviation 0.000896	0.00234 1/h Standard Deviation NA Standard deviation is not applicable for a sample size of 1.	0.00216 1/h Standard Deviation 0.000670

SECONDARY outcome

Timeframe: Estimated from final dose (samples collected on the last day of Cycle 3 [C3D28; each cycle is 28 days long], and Follow-up Visits 1 [C3D28 + 4 weeks], 2 [C3D28 + 10 weeks], and 3 [C3D28 + 16 weeks])

Population: The PK Population included all patients who had at least one quantifiable serum MOR00208 concentration. PK parameters were calculated as data permitted. Per pre-specified analysis plan, statistical summaries are provided overall, by NHL subtype, and for the combined group comprising FL patients + other iNHL patients.

Apparent terminal half-life calculated from ln(2)/λz

Outcome measures

Outcome measures
Measure	Total n=12 Participants All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	FL Subtype n=9 Participants Patients with follicular lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	DLBCL Subtype Patients with diffuse large B-cell lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	MCL Subtype n=2 Participants Patients with mantle cell lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	Other iNHL n=1 Participants Patients with other indolent non-Hodgkin's lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	FL + Other iNHL n=10 Participants Combined group of patients with follicular lymphoma and patients with other indolent non-Hodgkin's lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.
PK Parameter: Apparent Terminal Half-life (t[1/2]) of MOR00208	14.75111 days Standard Deviation 4.680075	14.87185 days Standard Deviation 4.863339	—	15.42457 days Standard Deviation 6.690102	12.31761 days Standard Deviation NA Standard deviation is not applicable for a sample size of 1.	14.61642 days Standard Deviation 4.655799

SECONDARY outcome

Timeframe: Estimated from final dose (samples collected on the last day of Cycle 3 [C3D28; each cycle is 28 days long], and Follow-up Visits 1 [C3D28 + 4 weeks], 2 [C3D28 + 10 weeks], and 3 [C3D28 + 16 weeks])

Population: The PK Population included all patients who had at least one quantifiable serum MOR00208 concentration. PK parameters were calculated as data permitted. Per pre-specified analysis plan, statistical summaries are provided overall, by NHL subtype, and for the combined group comprising FL patients + other iNHL patients.

Total body clearance calculated for single or multiple doses: dose(s)/AUC(0-inf)

Outcome measures

Outcome measures
Measure	Total n=91 Participants All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	FL Subtype n=33 Participants Patients with follicular lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	DLBCL Subtype n=35 Participants Patients with diffuse large B-cell lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	MCL Subtype n=12 Participants Patients with mantle cell lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	Other iNHL n=11 Participants Patients with other indolent non-Hodgkin's lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	FL + Other iNHL n=44 Participants Combined group of patients with follicular lymphoma and patients with other indolent non-Hodgkin's lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.
PK Parameter: Total Body Clearance (CL) of MOR00208	NA L/h Standard Deviation NA There were not sufficient data available to allow parameter estimation.	NA L/h Standard Deviation NA There were not sufficient data available to allow parameter estimation.	NA L/h Standard Deviation NA There were not sufficient data available to allow parameter estimation.	NA L/h Standard Deviation NA There were not sufficient data available to allow parameter estimation.	NA L/h Standard Deviation NA There were not sufficient data available to allow parameter estimation.	NA L/h Standard Deviation NA There were not sufficient data available to allow parameter estimation.

SECONDARY outcome

Timeframe: Estimated from final dose (samples collected on the last day of Cycle 3 [C3D28; each cycle is 28 days long], and Follow-up Visits 1 [C3D28 + 4 weeks], 2 [C3D28 + 10 weeks], and 3 [C3D28 + 16 weeks])

Population: The PK Population included all patients who had at least one quantifiable serum MOR00208 concentration. PK parameters were calculated as data permitted. Per pre-specified analysis plan, statistical summaries are provided overall, by NHL subtype, and for the combined group comprising FL patients + other iNHL patients.

Apparent volume of distribution during the terminal phase, calculated from dose/(AUC(0-inf)\*λz)

Outcome measures

Outcome measures
Measure	Total n=91 Participants All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	FL Subtype n=33 Participants Patients with follicular lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	DLBCL Subtype n=35 Participants Patients with diffuse large B-cell lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	MCL Subtype n=12 Participants Patients with mantle cell lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	Other iNHL n=11 Participants Patients with other indolent non-Hodgkin's lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	FL + Other iNHL n=44 Participants Combined group of patients with follicular lymphoma and patients with other indolent non-Hodgkin's lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.
PK Parameter: Apparent Volume of Distribution (Vz) of MOR00208	NA L Standard Deviation NA There were not sufficient data available to allow parameter estimation.	NA L Standard Deviation NA There were not sufficient data available to allow parameter estimation.	NA L Standard Deviation NA There were not sufficient data available to allow parameter estimation.	NA L Standard Deviation NA There were not sufficient data available to allow parameter estimation.	NA L Standard Deviation NA There were not sufficient data available to allow parameter estimation.	NA L Standard Deviation NA There were not sufficient data available to allow parameter estimation.

SECONDARY outcome

Timeframe: Cycle 1 Day 1 (Baseline) to Cycle 1: Days 8, 15, and 22; Cycles 2 and 3: Days 1, 15, and 28 (each cycle is 28 days); End of Study (up to 7.5 years)

Population: Pharmacodynamic samples were collected at timepoints through the study where possible. Per pre-specified analysis plan, statistical summaries are provided overall, by NHL subtype, and for the combined group comprising FL patients + other iNHL patients.

Actual change from baseline will be summarized descriptively by visit for the pharmacodynamic parameter: B-cell populations

Outcome measures

Outcome measures
Measure	Total n=70 Participants All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	FL Subtype n=26 Participants Patients with follicular lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	DLBCL Subtype n=31 Participants Patients with diffuse large B-cell lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	MCL Subtype n=8 Participants Patients with mantle cell lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	Other iNHL n=5 Participants Patients with other indolent non-Hodgkin's lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	FL + Other iNHL n=31 Participants Combined group of patients with follicular lymphoma and patients with other indolent non-Hodgkin's lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.
Absolute Change From Baseline in Measurements of B-cell Populations Cycle 2 Day 28	-27.68 10^6 cells/L Interval -59.0 to -8.0	-28.00 10^6 cells/L Interval -115.12 to -0.8	-14.50 10^6 cells/L Interval -35.0 to -1.97	-176.85 10^6 cells/L Interval -661.0 to -28.0	-38.00 10^6 cells/L Interval -120.0 to -4.0	-28.00 10^6 cells/L Interval -94.0 to -3.88
Absolute Change From Baseline in Measurements of B-cell Populations Cycle 3 Day 15	-36.50 10^6 cells/L Interval -135.72 to 0.0	-33.50 10^6 cells/L Interval -171.0 to 10.0	-22.00 10^6 cells/L Interval -241.0 to 21.0	-256.72 10^6 cells/L Interval -615.0 to -30.0	-77.00 10^6 cells/L Interval -127.0 to -6.0	-35.00 10^6 cells/L Interval -127.0 to 9.0
Absolute Change From Baseline in Measurements of B-cell Populations Cycle 1 Day 8	-13.60 10^6 cells/L Interval -50.25 to -1.0	-68.00 10^6 cells/L Interval -141.0 to -1.0	0.00 10^6 cells/L Interval -13.6 to 10.0	-61.13 10^6 cells/L Interval -214.2 to 7618.0	-65.00 10^6 cells/L Interval -108.0 to 13.0	-65.00 10^6 cells/L Interval -108.0 to -2.0
Absolute Change From Baseline in Measurements of B-cell Populations Cycle 1 Day 15	-15.00 10^6 cells/L Interval -55.94 to -3.0	-60.50 10^6 cells/L Interval -171.0 to -10.0	-3.00 10^6 cells/L Interval -15.0 to 6.0	-47.00 10^6 cells/L Interval -687.0 to 26570.0	-47.00 10^6 cells/L Interval -110.0 to 0.0	-57.00 10^6 cells/L Interval -110.02 to -10.0
Absolute Change From Baseline in Measurements of B-cell Populations Cycle 1 Day 22	-14.00 10^6 cells/L Interval -57.0 to -4.5	-34.00 10^6 cells/L Interval -148.0 to -6.0	-4.25 10^6 cells/L Interval -19.0 to 0.0	-65.01 10^6 cells/L Interval -680.0 to 1487.0	-60.00 10^6 cells/L Interval -120.0 to 33.0	-44.00 10^6 cells/L Interval -105.98 to -6.0
Absolute Change From Baseline in Measurements of B-cell Populations Cycle 2 Day 1	-14.00 10^6 cells/L Interval -51.71 to -3.6	-45.00 10^6 cells/L Interval -141.0 to -2.0	-4.00 10^6 cells/L Interval -17.0 to 1.0	-51.71 10^6 cells/L Interval -697.0 to 2025.0	-3.00 10^6 cells/L Interval -121.0 to 42.0	-34.00 10^6 cells/L Interval -116.39 to -2.0
Absolute Change From Baseline in Measurements of B-cell Populations Cycle 2 Day 15	-24.00 10^6 cells/L Interval -61.0 to -12.0	-47.50 10^6 cells/L Interval -181.21 to 0.0	-14.25 10^6 cells/L Interval -23.0 to -4.9	-61.45 10^6 cells/L Interval -673.0 to 9637.0	-56.00 10^6 cells/L Interval -120.0 to 20.0	-56.00 10^6 cells/L Interval -120.0 to -5.5
Absolute Change From Baseline in Measurements of B-cell Populations Cycle 3 Day 1	-36.00 10^6 cells/L Interval -117.99 to 0.0	-43.00 10^6 cells/L Interval -171.0 to 5.0	-16.00 10^6 cells/L Interval -238.0 to 0.0	-13.06 10^6 cells/L Interval -718.0 to 2.0	-68.00 10^6 cells/L Interval -129.0 to 16.0	-64.00 10^6 cells/L Interval -129.0 to 5.0
Absolute Change From Baseline in Measurements of B-cell Populations Cycle 3 Day 28	-46.00 10^6 cells/L Interval -94.0 to -8.37	-60.50 10^6 cells/L Interval -171.0 to 10.0	-16.50 10^6 cells/L Interval -124.8 to 35.0	-43.00 10^6 cells/L Interval -689.0 to 76.53	-59.00 10^6 cells/L Interval -129.0 to -5.0	-60.50 10^6 cells/L Interval -121.18 to -5.0
Absolute Change From Baseline in Measurements of B-cell Populations Study Completion/Early Termination	-15.00 10^6 cells/L Interval -69.82 to 4.0	-72.00 10^6 cells/L Interval -241.0 to 8.0	-1.67 10^6 cells/L Interval -22.1 to 7.0	-49.00 10^6 cells/L Interval -618.0 to 63413.0	-40.50 10^6 cells/L Interval -133.0 to 22.0	-72.00 10^6 cells/L Interval -240.0 to 8.0

SECONDARY outcome

Timeframe: Cycle 1 Day 1 (Baseline) to Cycle 1: Days 8, 15, and 22; Cycles 2 and 3: Days 1, 15, and 28 (each cycle is 28 days); End of Study (up to 7.5 years)

Population: Pharmacodynamic samples were collected at timepoints through the study where possible. Per pre-specified analysis plan, statistical summaries are provided overall, by NHL subtype, and for the combined group comprising FL patients + other iNHL patients.

Relative change from baseline will be summarized descriptively by visit for the pharmacodynamic parameter: B-cell populations

Outcome measures

Outcome measures
Measure	Total n=70 Participants All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	FL Subtype n=26 Participants Patients with follicular lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	DLBCL Subtype n=31 Participants Patients with diffuse large B-cell lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	MCL Subtype n=8 Participants Patients with mantle cell lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	Other iNHL n=5 Participants Patients with other indolent non-Hodgkin's lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	FL + Other iNHL n=31 Participants Combined group of patients with follicular lymphoma and patients with other indolent non-Hodgkin's lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.
Percent Change From Baseline in Measurements of B-cell Populations Cycle 1 Day 15	-50.00 percentage change from baseline Interval -79.422 to -32.353	-87.11 percentage change from baseline Interval -95.947 to -46.341	-32.35 percentage change from baseline Interval -67.442 to 11.429	-40.17 percentage change from baseline Interval -85.16 to 5060.952	-50.00 percentage change from baseline Interval -87.059 to 0.0	-82.71 percentage change from baseline Interval -94.253 to -46.341
Percent Change From Baseline in Measurements of B-cell Populations Study Completion/Early Termination	-49.31 percentage change from baseline Interval -85.444 to 2.941	-87.00 percentage change from baseline Interval -95.725 to -14.925	-45.44 percentage change from baseline Interval -52.5 to 37.5	-75.09 percentage change from baseline Interval -93.911 to 1429.186	-40.86 percentage change from baseline Interval -100.0 to 200.0	-87.00 percentage change from baseline Interval -95.122 to 8.696
Percent Change From Baseline in Measurements of B-cell Populations Cycle 1 Day 8	-42.07 percentage change from baseline Interval -70.588 to -2.793	-80.64 percentage change from baseline Interval -95.914 to -25.0	-0.64 percentage change from baseline Interval -49.333 to 72.857	-40.32 percentage change from baseline Interval -77.154 to 1451.048	-74.47 percentage change from baseline Interval -81.203 to 118.182	-76.47 percentage change from baseline Interval -85.116 to -25.0
Percent Change From Baseline in Measurements of B-cell Populations Cycle 1 Day 22	-55.88 percentage change from baseline Interval -82.625 to -27.5	-83.23 percentage change from baseline Interval -100.0 to -35.8	-35.77 percentage change from baseline Interval -67.857 to -5.714	-82.62 percentage change from baseline Interval -90.556 to 33.514	-63.83 percentage change from baseline Interval -90.226 to 71.739	-68.39 percentage change from baseline Interval -96.279 to -35.8
Percent Change From Baseline in Measurements of B-cell Populations Cycle 2 Day 1	-55.63 percentage change from baseline Interval -80.0 to -27.273	-82.65 percentage change from baseline Interval -94.312 to -25.102	-40.18 percentage change from baseline Interval -61.905 to 27.778	-72.03 percentage change from baseline Interval -85.171 to 45.639	-27.27 percentage change from baseline Interval -90.977 to 54.348	-80.18 percentage change from baseline Interval -92.093 to -25.102
Percent Change From Baseline in Measurements of B-cell Populations Cycle 2 Day 15	-73.80 percentage change from baseline Interval -83.542 to -57.407	-81.98 percentage change from baseline Interval -100.0 to -35.667	-67.32 percentage change from baseline Interval -83.542 to -31.25	-74.07 percentage change from baseline Interval -93.373 to 217.196	-71.76 percentage change from baseline Interval -100.0 to 43.478	-78.05 percentage change from baseline Interval -97.957 to -57.407
Percent Change From Baseline in Measurements of B-cell Populations Cycle 2 Day 28	-76.47 percentage change from baseline Interval -86.458 to -38.095	-87.25 percentage change from baseline Interval -100.0 to -7.143	-59.07 percentage change from baseline Interval -83.415 to -23.529	-71.67 percentage change from baseline Interval -96.062 to -30.769	-52.89 percentage change from baseline Interval -90.226 to -18.085	-82.87 percentage change from baseline Interval -94.419 to -18.085
Percent Change From Baseline in Measurements of B-cell Populations Cycle 3 Day 1	-79.63 percentage change from baseline Interval -94.585 to -3.666	-93.06 percentage change from baseline Interval -96.639 to 22.997	-82.64 percentage change from baseline Interval -98.333 to 142.105	-3.67 percentage change from baseline Interval -87.242 to 3.704	-76.06 percentage change from baseline Interval -96.992 to 145.455	-79.63 percentage change from baseline Interval -95.608 to 22.997
Percent Change From Baseline in Measurements of B-cell Populations Cycle 3 Day 15	-72.07 percentage change from baseline Interval -93.953 to -33.333	-76.61 percentage change from baseline Interval -96.479 to 48.78	-45.24 percentage change from baseline Interval -94.792 to 110.526	-72.07 percentage change from baseline Interval -74.727 to -55.556	-90.59 percentage change from baseline Interval -95.489 to -54.545	-90.59 percentage change from baseline Interval -96.39 to 0.0
Percent Change From Baseline in Measurements of B-cell Populations Cycle 3 Day 28	-80.00 percentage change from baseline Interval -95.833 to -53.191	-96.06 percentage change from baseline Interval -98.193 to -37.085	-66.27 percentage change from baseline Interval -87.847 to 184.211	-79.63 percentage change from baseline Interval -83.718 to 21.484	-66.60 percentage change from baseline Interval -96.992 to -45.455	-90.45 percentage change from baseline Interval -97.611 to -53.191

SECONDARY outcome

Timeframe: Cycle 1 Day 1 (Baseline) to Cycle 1: Days 8, 15, and 22; Cycles 2 and 3: Days 1, 15, and 28 (each cycle is 28 days); End of Study (up to 7.5 years)

Population: Pharmacodynamic samples were collected at timepoints through the study where possible. Per pre-specified analysis plan, statistical summaries are provided overall, by NHL subtype, and for the combined group comprising FL patients + other iNHL patients.

Actual change from baseline will be summarized descriptively by visit for the pharmacodynamic parameter: T-cell populations

Outcome measures

Outcome measures
Measure	Total n=71 Participants All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	FL Subtype n=26 Participants Patients with follicular lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	DLBCL Subtype n=30 Participants Patients with diffuse large B-cell lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	MCL Subtype n=9 Participants Patients with mantle cell lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	Other iNHL n=6 Participants Patients with other indolent non-Hodgkin's lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	FL + Other iNHL n=32 Participants Combined group of patients with follicular lymphoma and patients with other indolent non-Hodgkin's lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.
Absolute Change From Baseline in Measurements of T-cell Populations Cycle 1 Day 8	41.00 10^6 cells/L Interval -3.46 to 89.0	12.38 10^6 cells/L Interval -103.0 to 162.0	89.00 10^6 cells/L Interval 46.0 to 260.0	-55.92 10^6 cells/L Interval -219.0 to 600.0	16.00 10^6 cells/L Interval -1119.0 to 269.0	16.00 10^6 cells/L Interval -98.0 to 85.0
Absolute Change From Baseline in Measurements of T-cell Populations Cycle 1 Day 15	12.00 10^6 cells/L Interval -67.0 to 80.0	3.00 10^6 cells/L Interval -301.0 to 123.0	28.00 10^6 cells/L Interval -43.0 to 196.0	-22.00 10^6 cells/L Interval -193.0 to 1042.0	-94.00 10^6 cells/L Interval -1011.0 to 526.0	-19.00 10^6 cells/L Interval -297.79 to 110.0
Absolute Change From Baseline in Measurements of T-cell Populations Cycle 1 Day 22	-10.00 10^6 cells/L Interval -70.88 to 34.0	-31.00 10^6 cells/L Interval -180.0 to 34.0	26.00 10^6 cells/L Interval -114.0 to 184.0	-3.00 10^6 cells/L Interval -452.0 to 1129.5	-41.00 10^6 cells/L Interval -252.0 to 71.0	-36.00 10^6 cells/L Interval -180.0 to 26.0
Absolute Change From Baseline in Measurements of T-cell Populations Cycle 2 Day 1	17.50 10^6 cells/L Interval -100.0 to 61.0	-26.00 10^6 cells/L Interval -190.0 to 152.0	42.50 10^6 cells/L Interval -105.0 to 94.0	-96.00 10^6 cells/L Interval -531.11 to 127.61	-40.00 10^6 cells/L Interval -537.0 to 844.0	-40.00 10^6 cells/L Interval -137.0 to 111.0
Absolute Change From Baseline in Measurements of T-cell Populations Cycle 2 Day 15	88.00 10^6 cells/L Interval -9.0 to 152.0	59.98 10^6 cells/L Interval -117.0 to 153.0	72.00 10^6 cells/L Interval -115.0 to 184.0	164.00 10^6 cells/L Interval -9.0 to 719.03	54.50 10^6 cells/L Interval -28.0 to 422.0	59.98 10^6 cells/L Interval -72.0 to 153.0
Absolute Change From Baseline in Measurements of T-cell Populations Cycle 3 Day 15	110.00 10^6 cells/L Interval -27.0 to 318.0	94.00 10^6 cells/L Interval -111.93 to 383.0	203.50 10^6 cells/L Interval -517.0 to 462.0	599.00 10^6 cells/L Interval 143.0 to 770.01	-27.00 10^6 cells/L Interval -212.0 to 112.0	80.00 10^6 cells/L Interval -111.93 to 213.0
Absolute Change From Baseline in Measurements of T-cell Populations Cycle 3 Day 28	102.45 10^6 cells/L Interval -40.0 to 243.0	72.23 10^6 cells/L Interval -110.0 to 448.0	198.31 10^6 cells/L Interval -403.0 to 696.0	131.00 10^6 cells/L Interval -131.0 to 1279.07	72.50 10^6 cells/L Interval -78.0 to 366.0	72.50 10^6 cells/L Interval -40.0 to 366.0
Absolute Change From Baseline in Measurements of T-cell Populations Cycle 2 Day 28	99.00 10^6 cells/L Interval -17.0 to 250.0	32.87 10^6 cells/L Interval -120.8 to 286.0	176.64 10^6 cells/L Interval -142.0 to 386.0	133.00 10^6 cells/L Interval 39.32 to 1051.41	108.00 10^6 cells/L Interval -103.0 to 365.0	38.00 10^6 cells/L Interval -69.0 to 259.0
Absolute Change From Baseline in Measurements of T-cell Populations Cycle 3 Day 1	58.00 10^6 cells/L Interval -69.0 to 158.5	45.00 10^6 cells/L Interval -140.0 to 267.0	115.00 10^6 cells/L Interval -100.0 to 222.7	174.00 10^6 cells/L Interval 96.0 to 889.09	-32.00 10^6 cells/L Interval -203.0 to 90.0	-4.00 10^6 cells/L Interval -140.0 to 158.5
Absolute Change From Baseline in Measurements of T-cell Populations Study Completion/Early Termination	-57.50 10^6 cells/L Interval -137.0 to 144.0	-104.00 10^6 cells/L Interval -224.0 to 228.47	-84.00 10^6 cells/L Interval -305.0 to 139.0	165.00 10^6 cells/L Interval -174.0 to 361.17	361.50 10^6 cells/L Interval -1079.0 to 2592.0	-55.00 10^6 cells/L Interval -224.0 to 411.0

SECONDARY outcome

Timeframe: Cycle 1 Day 1 (Baseline) to Cycle 1: Days 8, 15, and 22; Cycles 2 and 3: Days 1, 15, and 28 (each cycle is 28 days); End of Study (up to 7.5 years)

Population: Pharmacodynamic samples were collected at timepoints through the study where possible. Per pre-specified analysis plan, statistical summaries are provided overall, by NHL subtype, and for the combined group comprising FL patients + other iNHL patients.

Relative change from baseline will be summarized descriptively by visit for the pharmacodynamic parameter: T-cell populations

Outcome measures

Outcome measures
Measure	Total n=71 Participants All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	FL Subtype n=26 Participants Patients with follicular lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	DLBCL Subtype n=30 Participants Patients with diffuse large B-cell lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	MCL Subtype n=9 Participants Patients with mantle cell lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	Other iNHL n=6 Participants Patients with other indolent non-Hodgkin's lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	FL + Other iNHL n=32 Participants Combined group of patients with follicular lymphoma and patients with other indolent non-Hodgkin's lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.
Percent Change From Baseline in Measurements of T-cell Populations Cycle 1 Day 15	1.75 percentage change from baseline Interval -9.999 to 12.312	1.25 percentage change from baseline Interval -17.2 to 14.604	8.81 percentage change from baseline Interval -15.314 to 44.118	-4.01 percentage change from baseline Interval -26.187 to 145.125	-17.49 percentage change from baseline Interval -43.187 to 31.687	-1.99 percentage change from baseline Interval -17.491 to 12.312
Percent Change From Baseline in Measurements of T-cell Populations Cycle 2 Day 15	10.39 percentage change from baseline Interval -1.17 to 22.944	7.34 percentage change from baseline Interval -11.716 to 23.043	15.35 percentage change from baseline Interval -11.358 to 38.971	12.25 percentage change from baseline Interval -1.17 to 107.003	3.46 percentage change from baseline Interval -7.91 to 18.026	6.82 percentage change from baseline Interval -7.91 to 22.944
Percent Change From Baseline in Measurements of T-cell Populations Cycle 2 Day 28	9.91 percentage change from baseline Interval -3.321 to 30.339	5.96 percentage change from baseline Interval -8.938 to 29.916	36.51 percentage change from baseline Interval -10.132 to 73.662	20.58 percentage change from baseline Interval 5.666 to 156.467	17.52 percentage change from baseline Interval -29.096 to 64.488	7.64 percentage change from baseline Interval -7.24 to 27.157
Percent Change From Baseline in Measurements of T-cell Populations Cycle 1 Day 8	7.28 percentage change from baseline Interval -0.394 to 16.991	1.59 percentage change from baseline Interval -8.906 to 18.456	17.07 percentage change from baseline Interval 10.242 to 37.132	-7.26 percentage change from baseline Interval -35.371 to 83.565	5.11 percentage change from baseline Interval -47.8 to 16.205	1.60 percentage change from baseline Interval -8.906 to 15.018
Percent Change From Baseline in Measurements of T-cell Populations Cycle 1 Day 22	-1.63 percentage change from baseline Interval -10.213 to 6.436	-1.83 percentage change from baseline Interval -13.413 to 6.436	5.62 percentage change from baseline Interval -20.394 to 39.28	-0.41 percentage change from baseline Interval -82.332 to 168.088	-10.76 percentage change from baseline Interval -38.693 to 22.684	-3.17 percentage change from baseline Interval -13.012 to 4.361
Percent Change From Baseline in Measurements of T-cell Populations Cycle 2 Day 1	2.93 percentage change from baseline Interval -12.484 to 12.025	-1.63 percentage change from baseline Interval -17.286 to 14.765	10.38 percentage change from baseline Interval -7.023 to 20.524	-12.48 percentage change from baseline Interval -76.529 to 14.538	-12.78 percentage change from baseline Interval -38.701 to 50.843	-2.36 percentage change from baseline Interval -17.286 to 14.765
Percent Change From Baseline in Measurements of T-cell Populations Cycle 3 Day 1	12.99 percentage change from baseline Interval -6.114 to 23.81	9.60 percentage change from baseline Interval -9.799 to 27.929	18.67 percentage change from baseline Interval -7.159 to 43.226	17.49 percentage change from baseline Interval 12.995 to 132.311	-2.37 percentage change from baseline Interval -35.866 to 28.754	-1.13 percentage change from baseline Interval -9.799 to 27.929
Percent Change From Baseline in Measurements of T-cell Populations Cycle 3 Day 15	20.09 percentage change from baseline Interval -7.627 to 34.934	9.57 percentage change from baseline Interval -12.21 to 34.934	20.66 percentage change from baseline Interval -14.13 to 100.873	44.73 percentage change from baseline Interval 26.047 to 114.59	-7.63 percentage change from baseline Interval -37.456 to 35.783	6.38 percentage change from baseline Interval -12.21 to 34.934
Percent Change From Baseline in Measurements of T-cell Populations Cycle 3 Day 28	17.34 percentage change from baseline Interval -9.783 to 26.905	11.37 percentage change from baseline Interval -13.423 to 33.794	21.90 percentage change from baseline Interval -18.26 to 151.965	23.86 percentage change from baseline Interval -9.783 to 190.346	17.10 percentage change from baseline Interval -13.781 to 32.588	14.15 percentage change from baseline Interval -11.156 to 32.588
Percent Change From Baseline in Measurements of T-cell Populations Study Completion/Early Termination	-8.07 percentage change from baseline Interval -14.994 to 26.912	-12.80 percentage change from baseline Interval -18.456 to 29.129	-8.07 percentage change from baseline Interval -42.093 to 32.548	12.32 percentage change from baseline Interval -31.694 to 52.042	28.31 percentage change from baseline Interval -65.0 to 457.951	-12.21 percentage change from baseline Interval -18.456 to 29.712

SECONDARY outcome

Timeframe: Cycle 1 Day 1 (Baseline) to Cycle 1: Days 8, 15, and 22; Cycles 2 and 3: Days 1, 15, and 28 (each cycle is 28 days); End of Study (up to 7.5 years)

Population: Pharmacodynamic samples were collected at timepoints through the study where possible. Per pre-specified analysis plan, statistical summaries are provided overall, by NHL subtype, and for the combined group comprising FL patients + other iNHL patients.

Actual change from baseline will be summarized descriptively by visit for the pharmacodynamic parameter: NK cell populations

Outcome measures

Outcome measures
Measure	Total n=71 Participants All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	FL Subtype n=26 Participants Patients with follicular lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	DLBCL Subtype n=30 Participants Patients with diffuse large B-cell lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	MCL Subtype n=9 Participants Patients with mantle cell lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	Other iNHL n=6 Participants Patients with other indolent non-Hodgkin's lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	FL + Other iNHL n=32 Participants Combined group of patients with follicular lymphoma and patients with other indolent non-Hodgkin's lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.
Absolute Change From Baseline in Measurements of NK Cell Populations Cycle 1 Day 8	-2.20 10^6 cells/L Interval -21.0 to 15.0	-20.00 10^6 cells/L Interval -38.0 to 15.0	20.00 10^6 cells/L Interval -10.0 to 41.0	-59.50 10^6 cells/L Interval -113.86 to 6.57	8.00 10^6 cells/L Interval -300.0 to 70.0	-20.00 10^6 cells/L Interval -38.0 to 15.0
Absolute Change From Baseline in Measurements of NK Cell Populations Cycle 1 Day 15	-23.00 10^6 cells/L Interval -43.0 to 11.0	-36.99 10^6 cells/L Interval -67.0 to 28.09	-4.00 10^6 cells/L Interval -26.25 to 23.0	-33.00 10^6 cells/L Interval -216.0 to 117.0	-79.00 10^6 cells/L Interval -211.0 to 66.0	-38.97 10^6 cells/L Interval -73.0 to 20.0
Absolute Change From Baseline in Measurements of NK Cell Populations Cycle 1 Day 22	-18.00 10^6 cells/L Interval -38.0 to 7.55	-28.00 10^6 cells/L Interval -48.0 to 7.55	27.06 10^6 cells/L Interval -24.0 to 71.0	-133.68 10^6 cells/L Interval -248.0 to -6.44	-60.00 10^6 cells/L Interval -345.0 to 42.0	-30.00 10^6 cells/L Interval -60.0 to 6.0
Absolute Change From Baseline in Measurements of NK Cell Populations Cycle 2 Day 1	-16.32 10^6 cells/L Interval -33.0 to 9.89	-11.01 10^6 cells/L Interval -39.73 to 21.0	-21.31 10^6 cells/L Interval -37.0 to 19.0	-64.00 10^6 cells/L Interval -249.0 to 556.03	-1.00 10^6 cells/L Interval -146.0 to 135.0	-7.00 10^6 cells/L Interval -31.0 to 21.0
Absolute Change From Baseline in Measurements of NK Cell Populations Cycle 2 Day 15	-19.00 10^6 cells/L Interval -32.0 to 16.8	6.00 10^6 cells/L Interval -29.0 to 35.0	-14.00 10^6 cells/L Interval -47.45 to 72.0	-116.65 10^6 cells/L Interval -144.0 to 199.59	-51.50 10^6 cells/L Interval -231.0 to 5.0	-7.00 10^6 cells/L Interval -29.0 to 27.37
Absolute Change From Baseline in Measurements of NK Cell Populations Cycle 2 Day 28	-1.00 10^6 cells/L Interval -18.0 to 51.0	-3.00 10^6 cells/L Interval -23.98 to 48.0	52.00 10^6 cells/L Interval -31.0 to 76.0	-93.00 10^6 cells/L Interval -181.27 to 10.43	9.50 10^6 cells/L Interval -260.0 to 245.0	-3.00 10^6 cells/L Interval -23.98 to 48.0
Absolute Change From Baseline in Measurements of NK Cell Populations Cycle 3 Day 1	-23.00 10^6 cells/L Interval -66.0 to -3.0	-10.00 10^6 cells/L Interval -37.0 to 10.74	-11.76 10^6 cells/L Interval -75.0 to 58.0	-104.00 10^6 cells/L Interval -111.26 to -66.0	-80.00 10^6 cells/L Interval -378.0 to 189.0	-23.00 10^6 cells/L Interval -66.0 to 10.74
Absolute Change From Baseline in Measurements of NK Cell Populations Cycle 3 Day 15	-33.00 10^6 cells/L Interval -70.0 to -2.0	-27.50 10^6 cells/L Interval -63.0 to 41.0	-46.00 10^6 cells/L Interval -75.8 to 158.0	-99.00 10^6 cells/L Interval -153.31 to -24.0	-84.00 10^6 cells/L Interval -97.0 to 88.0	-29.00 10^6 cells/L Interval -67.0 to 41.0
Absolute Change From Baseline in Measurements of NK Cell Populations Cycle 3 Day 28	-15.00 10^6 cells/L Interval -32.0 to 11.0	-5.66 10^6 cells/L Interval -28.0 to 51.0	0.62 10^6 cells/L Interval -58.0 to 108.0	-70.00 10^6 cells/L Interval -115.0 to -57.02	-13.50 10^6 cells/L Interval -93.0 to 103.0	-13.50 10^6 cells/L Interval -28.0 to 51.0
Absolute Change From Baseline in Measurements of NK Cell Populations Study Completion/Early Termination	-11.00 10^6 cells/L Interval -35.0 to 2.0	-11.50 10^6 cells/L Interval -35.0 to -2.0	-20.74 10^6 cells/L Interval -181.99 to 13.26	1.15 10^6 cells/L Interval -242.0 to 151.0	22.00 10^6 cells/L Interval -463.0 to 1924.0	-9.00 10^6 cells/L Interval -35.0 to 8.0

SECONDARY outcome

Timeframe: Cycle 1 Day 1 (Baseline) to Cycle 1: Days 8, 15, and 22; Cycles 2 and 3: Days 1, 15, and 28 (each cycle is 28 days); End of Study (up to 7.5 years)

Population: Pharmacodynamic samples were collected at timepoints through the study where possible. Per pre-specified analysis plan, statistical summaries are provided overall, by NHL subtype, and for the combined group comprising FL patients + other iNHL patients.

Relative change from baseline will be summarized descriptively by visit for the pharmacodynamic parameter: NK cell populations

Outcome measures

Outcome measures
Measure	Total n=71 Participants All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	FL Subtype n=26 Participants Patients with follicular lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	DLBCL Subtype n=30 Participants Patients with diffuse large B-cell lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	MCL Subtype n=9 Participants Patients with mantle cell lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	Other iNHL n=6 Participants Patients with other indolent non-Hodgkin's lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	FL + Other iNHL n=32 Participants Combined group of patients with follicular lymphoma and patients with other indolent non-Hodgkin's lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.
Percent Change From Baseline in Measurements of NK Cell Populations Cycle 1 Day 8	-1.62 percentage change from baseline Interval -18.261 to 11.429	-11.58 percentage change from baseline Interval -23.789 to 6.122	13.16 percentage change from baseline Interval -16.393 to 36.19	-32.20 percentage change from baseline Interval -43.326 to 3.99	13.79 percentage change from baseline Interval -48.94 to 194.444	-8.66 percentage change from baseline Interval -23.789 to 13.793
Percent Change From Baseline in Measurements of NK Cell Populations Cycle 1 Day 15	-18.85 percentage change from baseline Interval -24.046 to 11.364	-22.39 percentage change from baseline Interval -29.63 to 17.918	-1.14 percentage change from baseline Interval -21.078 to 33.333	-25.78 percentage change from baseline Interval -50.781 to 103.54	-32.11 percentage change from baseline Interval -49.421 to 183.333	-22.45 percentage change from baseline Interval -32.114 to 17.918
Percent Change From Baseline in Measurements of NK Cell Populations Cycle 1 Day 22	-13.38 percentage change from baseline Interval -29.688 to 3.027	-13.38 percentage change from baseline Interval -39.053 to 3.027	18.16 percentage change from baseline Interval -36.667 to 69.88	-50.87 percentage change from baseline Interval -78.0 to -4.347	-36.21 percentage change from baseline Interval -56.281 to 116.667	-14.59 percentage change from baseline Interval -39.053 to 2.597
Percent Change From Baseline in Measurements of NK Cell Populations Cycle 2 Day 1	-11.17 percentage change from baseline Interval -23.478 to 5.634	-8.03 percentage change from baseline Interval -25.573 to 11.896	-14.97 percentage change from baseline Interval -24.74 to 17.297	-50.00 percentage change from baseline Interval -53.667 to 337.684	-0.16 percentage change from baseline Interval -56.371 to 141.667	-6.48 percentage change from baseline Interval -25.573 to 11.896
Percent Change From Baseline in Measurements of NK Cell Populations Cycle 2 Day 15	-8.11 percentage change from baseline Interval -22.467 to 20.314	9.03 percentage change from baseline Interval -22.467 to 22.727	-7.13 percentage change from baseline Interval -31.429 to 60.0	-41.00 percentage change from baseline Interval -56.25 to 134.731	-20.08 percentage change from baseline Interval -37.684 to 8.621	-1.51 percentage change from baseline Interval -22.467 to 20.37
Percent Change From Baseline in Measurements of NK Cell Populations Cycle 2 Day 28	-1.92 percentage change from baseline Interval -14.762 to 29.73	-4.23 percentage change from baseline Interval -15.909 to 19.592	32.57 percentage change from baseline Interval -14.762 to 73.729	-48.44 percentage change from baseline Interval -68.976 to 6.334	35.32 percentage change from baseline Interval -42.414 to 261.111	-4.23 percentage change from baseline Interval -15.909 to 19.592
Percent Change From Baseline in Measurements of NK Cell Populations Cycle 3 Day 1	-14.08 percentage change from baseline Interval -26.866 to -1.115	-12.83 percentage change from baseline Interval -25.191 to 12.987	-8.33 percentage change from baseline Interval -35.545 to 50.0	-42.34 percentage change from baseline Interval -51.563 to -34.667	-31.97 percentage change from baseline Interval -61.664 to 525.0	-13.22 percentage change from baseline Interval -26.866 to 12.987
Percent Change From Baseline in Measurements of NK Cell Populations Cycle 3 Day 15	-20.13 percentage change from baseline Interval -38.253 to -1.136	-17.76 percentage change from baseline Interval -40.845 to 18.062	-16.17 percentage change from baseline Interval -39.336 to 124.576	-33.00 percentage change from baseline Interval -58.337 to -18.75	-32.43 percentage change from baseline Interval -39.431 to 244.444	-20.37 percentage change from baseline Interval -39.431 to 18.062
Percent Change From Baseline in Measurements of NK Cell Populations Cycle 3 Day 28	-6.10 percentage change from baseline Interval -21.697 to 17.0	-2.72 percentage change from baseline Interval -24.426 to 19.872	1.78 percentage change from baseline Interval -28.409 to 91.525	-38.33 percentage change from baseline Interval -54.688 to -21.697	-5.37 percentage change from baseline Interval -15.171 to 286.111	-5.37 percentage change from baseline Interval -18.182 to 19.872
Percent Change From Baseline in Measurements of NK Cell Populations Study Completion/Early Termination	-11.01 percentage change from baseline Interval -28.906 to 6.667	-11.06 percentage change from baseline Interval -28.333 to -0.866	-23.94 percentage change from baseline Interval -62.726 to 16.667	0.78 percentage change from baseline Interval -80.667 to 86.979	42.15 percentage change from baseline Interval -75.53 to 782.114	-10.49 percentage change from baseline Interval -28.333 to 22.222

SECONDARY outcome

Timeframe: From first dose until 30 days after last dose of MOR00208, up to 8.5 years

Population: Per pre-specified analysis plan, if CD19 expression on tumor cells was able to be measured in less than 15% of the ITT population at screening, the stratification analyses by baseline CD19 expression (as planned in the protocol) would not be performed. It was not possible to measure CD19 expression in sufficient cases for such an analysis to be meaningful.

Incidence of AEs as stratified by presence of CD19 on malignant lymphoma cells detected by tumor biopsy/aspirate during Screening

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: From first dose until Follow-up Visit 12, up to 4.5 years

Population: Per pre-specified analysis plan, if CD19 expression on tumor cells was able to be measured in less than 15% of the ITT population at screening, the stratification analyses by baseline CD19 expression (as planned in the protocol) would not be performed. It was not possible to measure CD19 expression in sufficient cases for such an analysis to be meaningful.

The analysis of the primary endpoint (ORR) will additionally be stratified by presence of CD19 on malignant lymphoma cells detected by tumor biopsy/aspirate during Screening

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: From first dose until 30 days after last dose of MOR00208, up to 8.5 years

Population: Genotyping for FcγRIIa and FcγRIIIa polymorphisms was performed for patients who consented to an optional mucosal cheek swab. Per pre-specified analysis plan, statistical summaries are provided overall, by NHL subtype, and for the combined group comprising FL patients + other iNHL patients.

Incidence of AEs as stratified by FcγRIIa polymorphism subgroups (genotypes HH, HR, or RR)

Outcome measures

Outcome measures
Measure	Total n=74 Participants All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	FL Subtype n=25 Participants Patients with follicular lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	DLBCL Subtype n=32 Participants Patients with diffuse large B-cell lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	MCL Subtype n=10 Participants Patients with mantle cell lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	Other iNHL n=7 Participants Patients with other indolent non-Hodgkin's lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	FL + Other iNHL n=32 Participants Combined group of patients with follicular lymphoma and patients with other indolent non-Hodgkin's lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.
Evaluation of AEs Stratified by FcγRIIa Polymorphism Genotype HH	210 adverse events	64 adverse events	109 adverse events	29 adverse events	8 adverse events	72 adverse events
Evaluation of AEs Stratified by FcγRIIa Polymorphism Genotype HR	188 adverse events	83 adverse events	51 adverse events	6 adverse events	48 adverse events	131 adverse events
Evaluation of AEs Stratified by FcγRIIa Polymorphism Genotype RR	61 adverse events	5 adverse events	44 adverse events	4 adverse events	8 adverse events	13 adverse events

SECONDARY outcome

Timeframe: From first dose until 30 days after last dose of MOR00208, up to 8.5 years

Population: Genotyping for FcγRIIa and FcγRIIIa polymorphisms was performed for patients who consented to an optional mucosal cheek swab. Per pre-specified analysis plan, statistical summaries are provided overall, by NHL subtype, and for the combined group comprising FL patients + other iNHL patients.

Incidence of AEs as stratified by FcγRIIIa polymorphism subgroups (genotypes FF, FV, or VV)

Outcome measures

Outcome measures
Measure	Total n=74 Participants All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	FL Subtype n=25 Participants Patients with follicular lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	DLBCL Subtype n=32 Participants Patients with diffuse large B-cell lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	MCL Subtype n=10 Participants Patients with mantle cell lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	Other iNHL n=7 Participants Patients with other indolent non-Hodgkin's lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	FL + Other iNHL n=32 Participants Combined group of patients with follicular lymphoma and patients with other indolent non-Hodgkin's lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.
Evaluation of AEs Stratified by FcγRIIIa Polymorphism Genotype VV	200 adverse events	26 adverse events	112 adverse events	6 adverse events	56 adverse events	82 adverse events
Evaluation of AEs Stratified by FcγRIIIa Polymorphism Genotype FF	110 adverse events	51 adverse events	59 adverse events	0 adverse events	0 adverse events	51 adverse events
Evaluation of AEs Stratified by FcγRIIIa Polymorphism Genotype FV	149 adverse events	75 adverse events	33 adverse events	33 adverse events	8 adverse events	83 adverse events

SECONDARY outcome

Timeframe: From first dose until Follow-up Visit 12, up to 4.5 years

Population: Genotyping for FcγRIIa and FcγRIIIa polymorphisms was performed for patients who consented to an optional mucosal cheek swab. Per pre-specified analysis plan, statistical summaries are provided overall, by NHL subtype, and for the combined group comprising FL patients + other iNHL patients.

The analysis of the primary endpoint (ORR) will additionally be stratified by FcγRIIa polymorphism subgroups (genotypes HH, HR, or RR)

Outcome measures

Outcome measures
Measure	Total n=74 Participants All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	FL Subtype n=25 Participants Patients with follicular lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	DLBCL Subtype n=32 Participants Patients with diffuse large B-cell lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	MCL Subtype n=10 Participants Patients with mantle cell lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	Other iNHL n=7 Participants Patients with other indolent non-Hodgkin's lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	FL + Other iNHL n=32 Participants Combined group of patients with follicular lymphoma and patients with other indolent non-Hodgkin's lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.
Evaluation of ORR Stratified by FcγRIIa Polymorphism Genotype HH	6 Participants	2 Participants	4 Participants	0 Participants	0 Participants	2 Participants
Evaluation of ORR Stratified by FcγRIIa Polymorphism Genotype HR	8 Participants	3 Participants	3 Participants	0 Participants	2 Participants	5 Participants
Evaluation of ORR Stratified by FcγRIIa Polymorphism Genotype RR	3 Participants	0 Participants	2 Participants	0 Participants	1 Participants	1 Participants

SECONDARY outcome

Timeframe: From first dose until Follow-up Visit 12, up to 4.5 years

Population: Genotyping for FcγRIIa and FcγRIIIa polymorphisms was performed for patients who consented to an optional mucosal cheek swab. Per pre-specified analysis plan, statistical summaries are provided overall, by NHL subtype, and for the combined group comprising FL patients + other iNHL patients.

The analysis of the primary endpoint (ORR) will additionally be stratified by FcγRIIIa polymorphism subgroups (genotypes FF, FV, or VV)

Outcome measures

Outcome measures
Measure	Total n=74 Participants All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	FL Subtype n=25 Participants Patients with follicular lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	DLBCL Subtype n=32 Participants Patients with diffuse large B-cell lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	MCL Subtype n=10 Participants Patients with mantle cell lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	Other iNHL n=7 Participants Patients with other indolent non-Hodgkin's lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	FL + Other iNHL n=32 Participants Combined group of patients with follicular lymphoma and patients with other indolent non-Hodgkin's lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.
Evaluation of ORR Stratified by FcγRIIIa Polymorphism Genotype FV	5 Participants	2 Participants	3 Participants	0 Participants	0 Participants	2 Participants
Evaluation of ORR Stratified by FcγRIIIa Polymorphism Genotype FF	10 Participants	1 Participants	6 Participants	0 Participants	3 Participants	4 Participants
Evaluation of ORR Stratified by FcγRIIIa Polymorphism Genotype VV	2 Participants	2 Participants	0 Participants	0 Participants	0 Participants	2 Participants

Adverse Events

Total

Serious events: 30 serious events

Other events: 77 other events

Deaths: 9 deaths

FL Subtype

Serious events: 7 serious events

Other events: 27 other events

Deaths: 1 deaths

DLBCL Subtype

Serious events: 18 serious events

Other events: 31 other events

Deaths: 6 deaths

MCL Subtype

Serious events: 2 serious events

Other events: 9 other events

Deaths: 2 deaths

Other iNHL

Serious events: 3 serious events

Other events: 10 other events

Deaths: 0 deaths

FL + Other iNHL

Serious events: 10 serious events

Other events: 37 other events

Deaths: 1 deaths

Serious adverse events

Serious adverse events
Measure	Total n=92 participants at risk All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	FL Subtype n=34 participants at risk Patients with follicular lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	DLBCL Subtype n=35 participants at risk Patients with diffuse large B-cell lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	MCL Subtype n=12 participants at risk Patients with mantle cell lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	Other iNHL n=11 participants at risk Patients with other indolent non-Hodgkin's lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	FL + Other iNHL n=45 participants at risk Combined group of patients with follicular lymphoma and patients with other indolent non-Hodgkin's lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.
Blood and lymphatic system disorders Anaemia	2.2% 2/92 • Number of events 4 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	0.00% 0/34 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	5.7% 2/35 • Number of events 4 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	0.00% 0/12 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	0.00% 0/11 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	0.00% 0/45 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).
Blood and lymphatic system disorders Febrile neutropenia	1.1% 1/92 • Number of events 1 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	0.00% 0/34 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	2.9% 1/35 • Number of events 1 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	0.00% 0/12 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	0.00% 0/11 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	0.00% 0/45 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).
Cardiac disorders Cardiac failure	1.1% 1/92 • Number of events 1 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	0.00% 0/34 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	2.9% 1/35 • Number of events 1 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	0.00% 0/12 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	0.00% 0/11 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	0.00% 0/45 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).
Eye disorders Vision blurred	1.1% 1/92 • Number of events 1 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	2.9% 1/34 • Number of events 1 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	0.00% 0/35 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	0.00% 0/12 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	0.00% 0/11 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	2.2% 1/45 • Number of events 1 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).
Gastrointestinal disorders Abdominal pain upper	1.1% 1/92 • Number of events 1 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	0.00% 0/34 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	2.9% 1/35 • Number of events 1 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	0.00% 0/12 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	0.00% 0/11 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	0.00% 0/45 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).
Gastrointestinal disorders Colitis	1.1% 1/92 • Number of events 1 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	0.00% 0/34 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	2.9% 1/35 • Number of events 1 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	0.00% 0/12 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	0.00% 0/11 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	0.00% 0/45 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).
Gastrointestinal disorders Gastrointestinal haemorrhage	1.1% 1/92 • Number of events 1 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	2.9% 1/34 • Number of events 1 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	0.00% 0/35 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	0.00% 0/12 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	0.00% 0/11 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	2.2% 1/45 • Number of events 1 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).
Hepatobiliary disorders Cholecystitis acute	1.1% 1/92 • Number of events 1 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	2.9% 1/34 • Number of events 1 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	0.00% 0/35 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	0.00% 0/12 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	0.00% 0/11 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	2.2% 1/45 • Number of events 1 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).
Infections and infestations Device related infection	1.1% 1/92 • Number of events 1 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	2.9% 1/34 • Number of events 1 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	0.00% 0/35 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	0.00% 0/12 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	0.00% 0/11 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	2.2% 1/45 • Number of events 1 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).
Infections and infestations Genital herpes zoster	1.1% 1/92 • Number of events 1 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	0.00% 0/34 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	2.9% 1/35 • Number of events 1 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	0.00% 0/12 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	0.00% 0/11 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	0.00% 0/45 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).
Infections and infestations Herpes zoster	2.2% 2/92 • Number of events 2 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	0.00% 0/34 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	2.9% 1/35 • Number of events 1 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	0.00% 0/12 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	9.1% 1/11 • Number of events 1 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	2.2% 1/45 • Number of events 1 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).
Infections and infestations Infected bite	1.1% 1/92 • Number of events 1 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	0.00% 0/34 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	2.9% 1/35 • Number of events 1 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	0.00% 0/12 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	0.00% 0/11 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	0.00% 0/45 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).
Infections and infestations Pneumococcal infection	1.1% 1/92 • Number of events 1 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	2.9% 1/34 • Number of events 1 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	0.00% 0/35 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	0.00% 0/12 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	0.00% 0/11 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	2.2% 1/45 • Number of events 1 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).
Infections and infestations Pneumonia	3.3% 3/92 • Number of events 5 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	0.00% 0/34 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	8.6% 3/35 • Number of events 5 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	0.00% 0/12 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	0.00% 0/11 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	0.00% 0/45 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).
Infections and infestations Respiratory tract infection	1.1% 1/92 • Number of events 1 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	2.9% 1/34 • Number of events 1 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	0.00% 0/35 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	0.00% 0/12 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	0.00% 0/11 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	2.2% 1/45 • Number of events 1 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).
Injury, poisoning and procedural complications Fracture	1.1% 1/92 • Number of events 1 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	0.00% 0/34 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	0.00% 0/35 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	0.00% 0/12 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	9.1% 1/11 • Number of events 1 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	2.2% 1/45 • Number of events 1 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).
Injury, poisoning and procedural complications Infusion related reaction	1.1% 1/92 • Number of events 1 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	2.9% 1/34 • Number of events 1 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	0.00% 0/35 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	0.00% 0/12 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	0.00% 0/11 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	2.2% 1/45 • Number of events 1 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Bone cancer	1.1% 1/92 • Number of events 1 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	0.00% 0/34 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	2.9% 1/35 • Number of events 1 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	0.00% 0/12 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	0.00% 0/11 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	0.00% 0/45 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Myelodysplastic syndrome	1.1% 1/92 • Number of events 1 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	2.9% 1/34 • Number of events 1 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	0.00% 0/35 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	0.00% 0/12 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	0.00% 0/11 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	2.2% 1/45 • Number of events 1 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).
Renal and urinary disorders Acute kidney injury	1.1% 1/92 • Number of events 1 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	2.9% 1/34 • Number of events 1 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	0.00% 0/35 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	0.00% 0/12 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	0.00% 0/11 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	2.2% 1/45 • Number of events 1 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).
Renal and urinary disorders Ureterolithiasis	1.1% 1/92 • Number of events 1 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	0.00% 0/34 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	2.9% 1/35 • Number of events 1 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	0.00% 0/12 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	0.00% 0/11 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	0.00% 0/45 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).
Respiratory, thoracic and mediastinal disorders Respiratory failure	1.1% 1/92 • Number of events 1 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	0.00% 0/34 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	2.9% 1/35 • Number of events 1 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	0.00% 0/12 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	0.00% 0/11 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	0.00% 0/45 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).
General disorders Disease progression	12.0% 11/92 • Number of events 12 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	5.9% 2/34 • Number of events 3 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	17.1% 6/35 • Number of events 6 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	16.7% 2/12 • Number of events 2 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	9.1% 1/11 • Number of events 1 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	6.7% 3/45 • Number of events 4 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).

Other adverse events

Other adverse events
Measure	Total n=92 participants at risk All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	FL Subtype n=34 participants at risk Patients with follicular lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	DLBCL Subtype n=35 participants at risk Patients with diffuse large B-cell lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	MCL Subtype n=12 participants at risk Patients with mantle cell lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	Other iNHL n=11 participants at risk Patients with other indolent non-Hodgkin's lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.	FL + Other iNHL n=45 participants at risk Combined group of patients with follicular lymphoma and patients with other indolent non-Hodgkin's lymphoma. All patients received 12 mg/kg MOR00208 administered as an intravenous infusion.
Blood and lymphatic system disorders Neutropenia	9.8% 9/92 • Number of events 12 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	5.9% 2/34 • Number of events 2 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	14.3% 5/35 • Number of events 8 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	8.3% 1/12 • Number of events 1 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	9.1% 1/11 • Number of events 1 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	6.7% 3/45 • Number of events 3 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).
Blood and lymphatic system disorders Thrombocytopenia	5.4% 5/92 • Number of events 14 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	0.00% 0/34 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	11.4% 4/35 • Number of events 12 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	8.3% 1/12 • Number of events 2 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	0.00% 0/11 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	0.00% 0/45 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).
Blood and lymphatic system disorders Lymphadenopathy	6.5% 6/92 • Number of events 9 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	5.9% 2/34 • Number of events 4 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	8.6% 3/35 • Number of events 4 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	8.3% 1/12 • Number of events 1 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	0.00% 0/11 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	4.4% 2/45 • Number of events 4 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).
Gastrointestinal disorders Nausea	9.8% 9/92 • Number of events 11 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	11.8% 4/34 • Number of events 6 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	5.7% 2/35 • Number of events 2 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	0.00% 0/12 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	27.3% 3/11 • Number of events 3 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	15.6% 7/45 • Number of events 9 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).
Gastrointestinal disorders Diarrhoea	8.7% 8/92 • Number of events 9 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	5.9% 2/34 • Number of events 2 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	14.3% 5/35 • Number of events 6 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	0.00% 0/12 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	9.1% 1/11 • Number of events 1 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	6.7% 3/45 • Number of events 3 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).
Gastrointestinal disorders Constipation	6.5% 6/92 • Number of events 7 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	5.9% 2/34 • Number of events 2 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	5.7% 2/35 • Number of events 3 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	8.3% 1/12 • Number of events 1 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	9.1% 1/11 • Number of events 1 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	6.7% 3/45 • Number of events 3 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).
General disorders Fatigue	8.7% 8/92 • Number of events 12 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	8.8% 3/34 • Number of events 5 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	8.6% 3/35 • Number of events 5 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	0.00% 0/12 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	18.2% 2/11 • Number of events 2 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	11.1% 5/45 • Number of events 7 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).
General disorders Oedema peripheral	8.7% 8/92 • Number of events 9 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	5.9% 2/34 • Number of events 2 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	14.3% 5/35 • Number of events 5 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	8.3% 1/12 • Number of events 2 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	0.00% 0/11 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	4.4% 2/45 • Number of events 2 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).
General disorders Asthenia	7.6% 7/92 • Number of events 9 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	8.8% 3/34 • Number of events 5 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	8.6% 3/35 • Number of events 3 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	8.3% 1/12 • Number of events 1 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	0.00% 0/11 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	6.7% 3/45 • Number of events 5 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).
General disorders Pyrexia	5.4% 5/92 • Number of events 8 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	5.9% 2/34 • Number of events 2 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	2.9% 1/35 • Number of events 2 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	8.3% 1/12 • Number of events 1 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	9.1% 1/11 • Number of events 3 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	6.7% 3/45 • Number of events 5 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).
Infections and infestations Upper respiratory tract infection	12.0% 11/92 • Number of events 14 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	20.6% 7/34 • Number of events 9 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	11.4% 4/35 • Number of events 5 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	0.00% 0/12 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	0.00% 0/11 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	15.6% 7/45 • Number of events 9 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).
Infections and infestations Bronchitis	6.5% 6/92 • Number of events 8 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	2.9% 1/34 • Number of events 1 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	11.4% 4/35 • Number of events 5 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	0.00% 0/12 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	9.1% 1/11 • Number of events 2 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	4.4% 2/45 • Number of events 3 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).
Injury, poisoning and procedural complications Infusion-related reaction	13.0% 12/92 • Number of events 15 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	11.8% 4/34 • Number of events 4 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	11.4% 4/35 • Number of events 6 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	16.7% 2/12 • Number of events 2 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	18.2% 2/11 • Number of events 3 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	13.3% 6/45 • Number of events 7 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).
Musculoskeletal and connective tissue disorders Back pain	7.6% 7/92 • Number of events 7 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	5.9% 2/34 • Number of events 2 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	5.7% 2/35 • Number of events 2 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	8.3% 1/12 • Number of events 1 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	18.2% 2/11 • Number of events 2 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	8.9% 4/45 • Number of events 4 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).
Nervous system disorders Headache	10.9% 10/92 • Number of events 15 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	8.8% 3/34 • Number of events 3 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	11.4% 4/35 • Number of events 7 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	8.3% 1/12 • Number of events 1 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	18.2% 2/11 • Number of events 4 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	11.1% 5/45 • Number of events 7 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).
Nervous system disorders Dizziness	9.8% 9/92 • Number of events 11 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	11.8% 4/34 • Number of events 4 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	5.7% 2/35 • Number of events 3 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	0.00% 0/12 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	27.3% 3/11 • Number of events 4 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	15.6% 7/45 • Number of events 8 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).
Psychiatric disorders Insomnia	7.6% 7/92 • Number of events 8 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	11.8% 4/34 • Number of events 5 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	2.9% 1/35 • Number of events 1 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	16.7% 2/12 • Number of events 2 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	0.00% 0/11 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	8.9% 4/45 • Number of events 5 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).
Respiratory, thoracic and mediastinal disorders Cough	8.7% 8/92 • Number of events 14 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	5.9% 2/34 • Number of events 3 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	11.4% 4/35 • Number of events 8 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	0.00% 0/12 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	18.2% 2/11 • Number of events 3 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	8.9% 4/45 • Number of events 6 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).
Respiratory, thoracic and mediastinal disorders Dyspnoea	7.6% 7/92 • Number of events 9 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	0.00% 0/34 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	11.4% 4/35 • Number of events 6 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	16.7% 2/12 • Number of events 2 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	9.1% 1/11 • Number of events 1 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).	2.2% 1/45 • Number of events 1 • Adverse events were collected from informed consent until 30 days after last dose of MOR00208, up to 8.5 years Patients were closely monitored for any kind of AE during the study. AEs were detected through physical examination, laboratory tests, or other assessments, or when volunteered by the patient in response to non-leading questioning during or between study visits. All SAEs are reported for the Safety Population, including events occurring prior to first dose of MOR00208. For non-serious AEs, only treatment-emergent events are reported (i.e., events occurring after first dose of MOR00208).

Additional Information

Medical Information

MorphoSys AG

Phone: +1 844 667-1992

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee
Publication restrictions are in place

Restriction type: GT60